The Effect of Extra Virgin Olive Oil in People With Multiple Sclerosis

University of Cyprus

Status: Active, not recruiting

Conditions: Multiple Sclerosis

Treatments: Dietary Supplement: High Phenolic Extra Virgin Olive Oil

Study type: Interventional

Funder types: Other

Identifiers

NCT04787497

NEEVOO.MS

Details and patient eligibility

About

This is an open label feasibility trial to examine the effect of a complementary treatment with High Phenolic Extra Virgin Olive Oil (HPEVOO) on the cognitive and mental health of people with Multiple Sclerosis (MS), while receiving their standard medical treatment.

Enrollment: 46 patients

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Clinical diagnosis of MS
• Must be between 18 to 65 years of age
• Both males and females are eligible for participation
• Must have at least five years of education
• Must be fluent in Greek language

Exclusion criteria

• Other neurological, psychiatric or chronic condition
• Enrollment in other trials/drug studies
• Experiencing side effects from previous treatments
• Inadequate visual and auditory acuity

Trial design

Primary purpose: Supportive Care

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

46 participants in 2 patient groups

Experimental Group

Experimental group

Description:

The Experimental Group will be receiving 50ml of freshly, cold-pressed, oleocanthal-rich Extra Virgin Olive Oil (EVOO) alongside their prescribed medical treatment. EVOO will be consumed on a daily basis for 12 months and all participants will undergo a neuropsychological assessment at baseline, 6 months and 12 months +/- 7 days after their first assessment or beginning of supplementation.

Treatment:

Dietary Supplement: High Phenolic Extra Virgin Olive Oil

Control Group

No Intervention group

Description:

The Control Group will be continuing their standard medical treatment without additional supplementation. The neuropsychological assessment will be conducted at baseline, 6 months and 12 months +/- 7 days after their first assessment.